Compare Adaptive Biotechnologies Corp (ADPT) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Bit Digital Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Bit Digital Inc trades at $1.64 (market cap $583.11M). The key difference: Adaptive Biotechnologies Corp is far larger — about 5.7× Bit Digital Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | BTBT | |
|---|---|---|
Market Cap | $3.33B | $583.11M |
Sector | Health | Technology |
52-Week High | $22.37 | $4.22 |
52-Week Low | $10.24 | $1.27 |
Enterprise Value | $3.19B | $872.41M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
BTBT trades at $1.74, up 5.45% in the past 24 hours, but faces bearish technical signals with 14 sell indicators. The company reported a net loss of $80.32 million in 2025 with a negative net income margin of -145.45%, though revenue reached $113.56 million. Recent news highlights a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase, signaling strategic moves in AI infrastructure and digital assets.
The outlook remains challenging due to persistent losses and high cash burn, but analyst consensus is 100% buy with potential from strategic investments. Key risks include execution on new ventures, competitive pressures, and reliance on financing amid negative operating cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
